Helsinn Group signs exclusive agreements with Mundipharma for distribution and licence of anamorelin in Brazil and across key markets in the Middle East and North Africa 11 February 2015
Helsinn Group signs exclusive agreement with Mundipharma for distribution and licensing of Netupitant/Palonosetron (nepa) in Brazil 10 February 2015
Helsinn and Zealand announce the advance of elsiglutide into Phase IIB development for the prevention of chemotherapyinduced diarrhea 6 February 2015
Helsinn Group grants stendhal international exclusive rights to the distribution and marketing of Netupitant-Palonosetron (nepa) in multiple countries of Latin America 3 February 2015
Helsinn to provide an independent educational grant support for a satellite symposium on Comprehensive Cancer Care 12 July 2014
Linkedin